Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 11,406 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Interventions: Avelumab, Cetuximab; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 428
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 274 more

Conditions: Parkinson's Disease
Interventions: ExAblate Transcranial MRgFUS, Sham ExAblate Transcranial MRgFUS; Device
Lead sponsor: InSightec; Industry
Eligibility: 30 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Charlottesville, Virginia • Seattle, Washington

Conditions: Mild to Heavy Alcohol Consumption
Interventions: Oxycodone; Other
Lead sponsor: University of Washington; Other
Eligibility: 35 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Psoriasis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Postpartum, Lactation, Drugs in Breast Milk, Mammary Drug Transporters, BCRP, OCT1
Interventions: Cimetidine 200 MG; Drug
Lead sponsor: University of Washington; Other
Eligibility: 14 Days to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Duarte, California • Stanford, California + 14 more

Conditions: Impaired Glucose Tolerance
Interventions: Aerobic exercise; Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 55 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Seattle, Washington • Tacoma, Washington

Conditions: Aneurysm, Vasospasm
Interventions: transluminal ballooning, currently existing therapies for the treatment of vasospasm; Procedure · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 17 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 3
States / cities: Sacramento, California • Nashville, Tennessee • Seattle, Washington

Conditions: Type1 Diabetes Mellitus
Interventions: Beta Cell Loss and Immune Function, Immune Function with RNAseq; Diagnostic Test · Other
Lead sponsor: University of Exeter; Other
Eligibility: Up to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Crohn's Disease
Interventions: Etrasimod, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 192
States / cities: Dothan, Alabama • Mobile, Alabama • Peoria, Arizona + 62 more

Conditions: Migraine, Chronic Headache
Interventions: Topiramate; Drug
Lead sponsor: Emerald City Headache Organization; Other
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 70
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 42 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: AIDS-Related Primary Effusion Lymphoma
Interventions: Laboratory Biomarker Analysis, Medical Chart Review; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: La Jolla, California • Los Angeles, California • Miami, Florida + 3 more

Conditions: Lung Cancer, Pulmonary Complications
Interventions: educational intervention, supervised exercise program; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 60
States / cities: Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more

Conditions: Cystic Fibrosis
Interventions: VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more

Conditions: Pancreatic Cancer
Interventions: cetuximab, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 382
States / cities: Mobile, Alabama • Opelika, Alabama • Anchorage, Alaska + 276 more

Conditions: Ovarian Cancer
Interventions: BCG vaccine, autologous tumor cell vaccine, carboplatin, cisplatin, cyclophosphamide, paclitaxel, dinitrophenyl, surgical procedure; Biological · Drug · Other + 1 more
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 59
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 52 more

Conditions: Precocious Puberty, Central
Interventions: Leuprolide Acetate 45 mg; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 2 Years to 9 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 10
States / cities: San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more

Conditions: Neisseria Gonorrhoeae Infection
Interventions: Ciprofloxacin 500 mg; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lumbar Puncture
Interventions: Compass Lumbar Puncture Enhanced; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Fibrolamellar Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Childhood Fibrolamellar Carcinoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Fibrolamellar Carcinoma, Refractory Malignant Solid Neoplasm
Interventions: Bcl-XL Proteolysis Targeting Chimera DT2216, Biospecimen Collection, Irinotecan; Biological · Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 39 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more

Conditions: Cancer
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 50,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 23 more

Conditions: Age - Related Macular Degeneration (AMD)
Interventions: Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more

Search by objective public record fields.

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease

Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Drug Excretion in Breast Milk

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Cognitive Effects of Aerobic Exercise for IGT Adults

Balloon Prophylaxis of Aneurysmal Vasospasm

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Does Topiramate Adjust the Excitability of the Brain in Migraine Sufferers?

Comparison of ddI Versus Zidovudine in HIV-Infected Patients

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

Pediatric Lumbar Puncture Success Using the COMPASS

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Childhood Cancer Survivor Study

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)